Log In
Print
BCIQ
Print
Print this Print this
 

Atripla, emtricitabine/tenofovir/efavirenz

Also known as: Viread/Sustiva/Emtriva

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionOnce-daily combination tablet of Truvada emtricitabine/tenofovir and BMY's Sustiva efavirenz
Molecular Target
Mechanism of Action 
Latest Stage of DevelopmentMarketed
IndicationHIV / AIDS
Partner

Bristol-Myers Squibb Co.; Merck & Co. Inc.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today